Gita Thanarajasingam(@GitaThanaMD) 's Twitter Profileg
Gita Thanarajasingam

@GitaThanaMD

Physician and researcher in lymphoma and toxicity of cancer treatment. Assoc. Prof of Medicine at Mayo Clinic. Tweets & opinions mine. On a Twitter hiatus :)

ID:737651531239985153

calendar_today31-05-2016 14:26:44

218 Tweets

910 Followers

239 Following

Gita Thanarajasingam(@GitaThanaMD) 's Twitter Profile Photo

Congrats to our Mayo Hematology Division & lymphoma chair Steve Ansell & team on the publication of ECHELON-1 OS results! ⁦Mayo Clinic Comprehensive Cancer Center⁩ ⁦Mayo Clinic⁩ ⁦⁩ ⁦Carrie Thompson, MD⁩ ⁦Arushi Khurana⁩ ⁦⁦⁦Greg⁩ ⁦ nejm.org/doi/full/10.10…

account_circle
Andrew M. Evens, DO, MBA, MSc(@DrAEvens) 's Twitter Profile Photo

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s | NEJM

🙌 Kudos to Mayo Clinic Dr Ansell for leading this pivotal publication and landmark advance in the field.


nejm.org/doi/full/10.10…

account_circle
Andrew M. Evens, DO, MBA, MSc(@DrAEvens) 's Twitter Profile Photo

Looking forward to the Scientific Workshop June 23-24 (via Lymphoma Research Foundation) w/ focus on reviewing current state of AYA lymphoma, gaps in research & understanding of the diseases.

Follow along for updates throughout the meeting!



lymphoma.org/aboutlrf/resea…

account_circle
Gita Thanarajasingam(@GitaThanaMD) 's Twitter Profile Photo

Our esteemed newly minted Mayo MN Hematology div chair & Hodgkin lymphoma expert extraordinaire Steve Ansell presenting OS results of ECHELON-1 - practice changing for newly dx adv HL at Greg Carrie Thompson, MD Yucai Wang, MD, PhD usama durani Mayo Clinic Comprehensive Cancer Center Mayo Clinic ASCO

Our esteemed newly minted Mayo MN Hematology div chair & Hodgkin lymphoma expert extraordinaire Steve Ansell presenting OS results of ECHELON-1 - practice changing for newly dx adv HL at #ASCO22 @GregNowakowski @CaThompsonMD @YucaiWangMD @UDurani @MayoCancerCare @MayoClinic @ASCO
account_circle
Ethan Basch(@EthanBasch1) 's Twitter Profile Photo

Excited to present at , the PRO-TECT multicenter randomized trial of a PRO digital tool for symptom monitoring in US oncology practices, with simultaneous publication in JAMA JAMA, in the ASCO Plenary Series update session, 6/5/22 5:30pm EDT. Alliance for Clinical Trials in Oncology The Patient-Centered Outcomes Research Institute

Excited to present at #ASCO22, the PRO-TECT multicenter randomized trial of a PRO digital tool for symptom monitoring in US oncology practices, with simultaneous publication in JAMA @JAMA_current, in the ASCO Plenary Series update session, 6/5/22 5:30pm EDT. @ALLIANCE_org @PCORI
account_circle
Jan Geissler(@jangeissler) 's Twitter Profile Photo

A The Lancet Haematology Commission of patient advocates, clinicians, regulators, biostatisticians, pharmacists provides recomms on AE reporting, PRO, long-term tox reporting, patient involvement in AE. Read: thelancet.com/commissions/ha… - Mentions WECAN Acute Leukemia Advocates Network (ALAN) Myeloma Patients Europe

A @TheLancetHaem Commission of patient advocates, clinicians, regulators, biostatisticians, pharmacists provides recomms on AE reporting, PRO, long-term tox reporting, patient involvement in AE. Read: thelancet.com/commissions/ha… - Mentions @WECANadvocate @AcuteLeuk @MyelomaEurope
account_circle
Gita Thanarajasingam(@GitaThanaMD) 's Twitter Profile Photo

Thank you LUNGevity Foundation! It was an honor to present at on the relevance of patient generated data to cancer treatment tolerability along with colleagues from FDA, industry and an esteemed pt advocate Paul Kluetz FDA Oncology Mayo Clinic Comprehensive Cancer Center

account_circle